Clinical Trial Update: A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

This clinical trial update indicates the Phase 1, first-in-human study of GENA-104A16 in patients with advanced solid tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• GENA-104A16

Snippet

Sponsor: Genome & Company | Conditions: Advanced Solid Tumors | Phase 1 | Status: WITHDRAWN